AstraZeneca AB v. Wockhardt Bio AG
1:14-cv-00667
Overview
Parties
Defendant
AstraZeneca AB NPE (Individual / Inventor)
Represented By
4 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Counter Claimant
Wockhardt Bio AG NPE (Individual / Inventor)
Represented By
7 Attorneys ListedFaegre Drinker Biddle & Reath LLP
One Logan Square, Suite 2000
Whiteford, Taylor & Preston LLC
Whiteford, Taylor & Preston LLC, 600 N. King Street
Eckert Seamans Cherin & Mellott, LLC
Eckert Seamans Cherin & Mellott, LLC, 222 Delaware Avenue, 7th Floor
Wockhardt USA LLC Operating Company
Represented By
3 Attorneys ListedFaegre Drinker Biddle & Reath LLP
One Logan Square, Suite 2000
Whiteford, Taylor & Preston LLC
Whiteford, Taylor & Preston LLC, 600 N. King Street
Eckert Seamans Cherin & Mellott, LLC
Eckert Seamans Cherin & Mellott, LLC, 222 Delaware Avenue, 7th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 79,514,000 Asserted | Asserted Patent | View Official Patent → |
AstraZeneca AB v. Sun Pharma Global FZE
AstraZeneca AB v. Aurobindo Pharma Ltd.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
| US79514000 |
Filed: β
Issued: β
|
Term Verification Pending
Expires: β
|
|
|
USRE44186
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
Filed: 2011-12-01
Issued: 2013-04-30
|
Expired (Term Ended)
Expires: 2023-07-31
|
|
|
US7951400
Coated tablet formulation and method
|
Filed: 2005-05-25
Issued: 2011-05-31
|
Active (2.0 yrs remaining)
+1285d PTA
Expires: 2028-11-30
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked (3.5, 7.5, 11.5 Years).